ClinicalTrials.gg
RecruitingNCT07592546THRIVEUpdated Oct 26, 2026

Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

A Phase 4 interventional study of semaglutide in Class I/II Obesity, sponsored by Alain Dagher. Recruiting at 1 site in Canada. Open to participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionObesityRegistry: Weight LossReclassifiedWhy we changed it
Registry
Weight Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Weight Loss is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alain Dagher · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
35 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.

Planned enrollment
34th of 145
240 · median 100
Started
2026
with 29 others
Phase 4
40 of 145
20 open now
Primary completion
2028-12
later than 65 of 78 live
Registered
120th of 145
by date

Among the 145 studies testing semaglutide in Obesity, this one is the 34th largest by planned enrollment, is one of 30 that started in 2026, is one of 40 in phase 4, reaches primary completion later than 65 of the 78 other live ones, and was the 120th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

64 more — sign in →

By country, each count listing its studies:

All 70 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 35 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are:

  • Will excessive fat be associated with brain abnormalities on MRI measures?
  • Will weight loss change brain health on MRI measures?

Participants will:

  • Self-administer study drug, semaglutide, once a week for 80 weeks
  • Complete metabolic and basic body measurements
  • Complete cognitive, mood, and dietary assessments
  • Complete questionnaires
  • Undergo MRIs
Read the detailed description

We conducted a priori power calculations (80% power, α=0.05) based on published effect sizes (Cohen's d) for the following measures comparing obese to lean participants: hypothalamic neuroinflammation (d=1.52, required n=8/group; Thaler et al. 2012); cerebral metabolic rate of O₂ (d=1.59, required n=8/group; Anwar et al. 2022); oxygen extraction fraction (OEF) (d=0.67, required n=37/group; Anwar et al. 2022); white matter fractional anisotropy (d=0.61, required n=43/group; Daoust et al. 2021); and for the following measures following bariatric surgery: OEF (d=0.47, required n=37; Anwar et al. 2022); cerebral blood flow (d=0.74, required n=17; Anwar et al. 2022); fALFF (d=1.60, required n=6; Zeighami et al. 2021); cortical thickness (d=0.78, required n=8; Bohon et al. 2018).

Based on the above, we will assume a conservative minimum sample size of 43 per group to detect changes in brain health. In line with previous clinical trials for weight loss, where 88% of patients completed the trial but 83% adhered to the treatment regimen, we will assume a 15% attrition rate. Therefore, the minimum sample size providing adequate statistical power for sex-stratified analyses will be 50 men and 50 women. We will enroll 60 participants per group to account for an additional 20% dropout, for a total target sample of 120. At full enrollment, this will allow us to detect small to medium effects in brain health with over 90% power (Cohen's d=0.30), and sex-stratified analyses will be powered to detect medium effect sizes (Cohen's d=0.40) with 80% power.

If enrollment falls below 100 total participants (50 per group) for feasibility reasons, the sample might be considered insufficient to support confirmatory sex-stratified analyses. In this event, analyses will be conducted in the total sample only. Sex differences may then be examined in an exploratory capacity. This decision rule is pre-specified and will be applied without reference to outcome data.

Anwar, Nareen, Wesley J. Tucker, Nancy Puzziferri, T. Jake Samuel, Vlad G. Zaha, Ildiko Lingvay, Jaime Almandoz, et al. 2022. "Cognition and Brain Oxygen Metabolism Improves after Bariatric Surgery-Induced Weight Loss: A Pilot Study." Frontiers in Endocrinology 13 (December): 954127.

Bohon, Cara, Luis C. Garcia, and John M. Morton. 2018. "Changes in Cerebral Cortical Thickness Related to Weight Loss Following Bariatric Surgery." Obesity Surgery 28 (8): 2578-82.

Daoust, Justine, Joelle Schaffer, Yashar Zeighami, Alain Dagher, Isabel García-García, and Andréanne Michaud. 2021. "White Matter Integrity Differences in Obesity: A Meta-Analysis of Diffusion Tensor Imaging Studies." Neuroscience and Biobehavioral Reviews 129 (October): 133-41.

Thaler, Joshua P., Chun Xia Yi, Ellen A. Schur, Stephan J. Guyenet, Bang H. Hwang, Marcelo O. Dietrich, Xiaolin Zhao, et al. 2012. "Obesity Is Associated with Hypothalamic Injury in Rodents and Humans." The Journal of Clinical Investigation 122 (1): 153.

Zeighami, Yashar, Sylvain Iceta, Mahsa Dadar, Mélissa Pelletier, Mélanie Nadeau, Laurent Biertho, Annie Lafortune, et al. 2021. "Spontaneous Neural Activity Changes after Bariatric Surgery: A Resting-State FMRI Study." NeuroImage 241 (November): 118419.

03

Conditions studied

  • Class I/II Obesity

Browse trials for

Keywords

  • weight loss
  • BMI
  • Obesity
  • overweight
  • obese
  • semaglutide
  • Ozempic
  • Wegovy
  • GLP-1
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 240 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with Alain Dagher as lead sponsor.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key inclusion criteria for obese group:

  • Individuals of age 35-55 years with 27 - 40 kg/m2
  • Able to provide
  • Willing to self-inject semaglutide and follow study procedures for its entire duration.

Key inclusion criteria for lean control group:

  • Individuals of age 35-55 years with BMI 20 - 25 kg/m2
  • Able to provide informed consent

Exclusion criteria

Exclusion Criteria for both groups:

  • Current type 2 diabetes mellitus;
  • Neurological disorders affecting the CNS;
  • History or family history of medullary thyroid carcinoma or MEN2 syndrome
  • CNS-active medications (outside of medications used to control psychiatric disorders);
  • Poorly controlled psychiatric disorders including major depression or previous suicidality;
  • Class III obesity (>40 or BMI>35 with complications) as these individuals are eligible for bariatric surgery in Canada and will be referred for appropriate medical care;
  • Clinical safety blood measures indicative of a medical issue.
  • History of weight change > 5 kg in past 90 days;
  • History of pancreatitis
  • Previous or planned bariatric surgery;
  • Use of another weight loss medication during trial participation and within 90 days before enrolment;
  • History of serious medical illness, monogenic obesity, uncontrolled hypertension (sBP>160 mmHg, dBP>100 mmHg), active , illicit substance use, cigarette smoking, diagnosed eating disorder, as listed in the study protocol associated with; Other obesity comorbidities, e.g. hypertension, pre-diabetes ( = 6% to 6.4%), hyperlipidemia, controlled depressive disorder or anxiety, ADHD, and polycystic ovary syndrome, will not be exclusion criteria as this would reduce the representativeness of our sample.
  • Female subjects of (i.e., a premenopausal female capable of becoming pregnant) are eligible to enroll if they are either sexually inactive/abstinent or using an effective from screening until 4 weeks after the last dose. Medically accepted contraception are hormonal implants, hormonal patches, IDU, diaphragm and spermicide, cervical cape with spermicide, and condom with spermicide.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Overweight Group (BMI 27 - 40 kg/m2)

    semaglutide

    Drug: semaglutide

  • No intervention
    Lean group (BMI 20 - 25 kg/m2)

Interventions

  • Treatment will be given for 80 weeks. Dose will be escalated from 0.25 mg to a max of 2.4 mg per week.

    Also known as: Ozempic, Wegovy

07

What researchers measure

Primary outcomes

  1. Serum C-reactive Protein (CRP)

    Fasting serum CRP concentration (mg/L)

    Time frame: Baseline & Change from Baseline

  2. Serum Pro-inflammatory Cytokines (Interleukin-6, TNF-α, Interleukin-1β, and IL-1 Receptor Antagonist)

    Fasting serum concentrations of IL-6, TNF-α, IL-1β, and IL-1 receptor antagonist (all in pg/mL)

    Time frame: Baseline & Change from Baseline

  3. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    HOMA-IR is calculated as (fasting glucose \[mmol/L\] × fasting insulin \[μIU/mL\]) / 22.5. The resulting dimensionless value estimates insulin resistance; higher values indicate greater insulin resistance.

    Time frame: Baseline & Change from Baseline

  4. Fasting Plasma Glucose

    Venous plasma glucose concentration (mmol/L) following an overnight fast

    Time frame: Baseline & Change from Baseline

  5. Glycated Hemoglobin A1c (HbA1c)

    Percentage of glycated hemoglobin (%), reflecting mean blood glucose

    Time frame: Baseline & Change from Baseline

  6. Serum Leptin

    Fasting serum leptin concentration (ng/mL)

    Time frame: Baseline & Change from Baseline

  7. Serum Ghrelin

    Fasting serum ghrelin concentration (pg/mL)

    Time frame: Baseline & Change from Baseline

  8. Serum Adiponectin

    Fasting serum adiponectin concentration (μg/mL)

    Time frame: Baseline & Change from Baseline

  9. Fasting Serum Insulin

    Fasting serum insulin concentration (μIU/mL)

    Time frame: Baseline & Change from Baseline

  10. Serum Glucagon-Like Peptide-1 (GLP-1)

    Serum total GLP-1 concentration (pmol/L)

    Time frame: Baseline & Change from Baseline

  11. Serum C-peptide

    Fasting serum C-peptide concentration (nmol/L)

    Time frame: Baseline & Change from Baseline

  12. Serum Lipid Panel (Total Cholesterol, HDL Cholesterol, LDL Cholesterol, Triglycerides, and Non-Esterified Fatty Acids [NEFA])

    Fasting serum concentrations of total cholesterol, HDL, LDL, triglycerides, and NEFA (mmol/L)

    Time frame: Baseline & Change from Baseline

  13. Serum Apolipoprotein B (ApoB)

    Fasting serum ApoB concentration (g/L)

    Time frame: Baseline & Change from Baseline

  14. Red Blood Cell Phospholipid Fatty Acid Composition

    Proportion of individual fatty acid species in red blood cell membrane phospholipids (expressed as % of total fatty acids)

    Time frame: Baseline & Change from Baseline

  15. Cerebral Blood Flow as Measured by Pseudo-Continuous Arterial Spin Labeling (pCASL) MRI

    Regional and whole-brain cerebral blood flow (mL/100g/min) derived from pCASL sequences at 3T MRI

    Time frame: Baseline & Change from Baseline

  16. Oxygen Extraction Fraction (OEF) as Measured by Quantitative Susceptibility Mapping (QSM) and T2* MRI

    Whole-brain or regional OEF (dimensionless ratio, 0-1) derived from combined QSM and T2\* imaging

    Time frame: Baseline & Change from Baseline

  17. Cerebral Metabolic Rate of Oxygen (CMRO₂) as Measured by QSM and T2* MRI

    CMRO₂ (μmol/100g/min) estimated from OEF and cerebral blood flow

    Time frame: Baseline & Change from Baseline

  18. Cortical Thickness as Measured by Structural MRI

    Mean cortical thickness (mm) derived from T1-weighted

    Time frame: Baseline & Change from Baseline

  19. Grey Matter Volume as Measured by Structural MRI

    Regional and total grey matter volume (cm³) derived from T1-weighted structural MRI

    Time frame: Baseline & Change from Baseline

  20. Grey Matter Surface Area as Measured by Structural MRI

    Cortical surface area (cm²) derived from T1-weighted structural MRI

    Time frame: Baseline & Change from Baseline

  21. White Matter Fractional Anisotropy (FA) as Measured by Diffusion Tensor Imaging (DTI)

    FA (dimensionless, 0-1) derived from DTI; higher FA indicates greater white matter tract coherence

    Time frame: Baseline & Change from Baseline

  22. White Matter Mean Diffusivity (MD) as Measured by Diffusion Tensor Imaging (DTI)

    MD (mm²/s) derived from DTI; higher MD may indicate white matter disruption

    Time frame: Baseline & Change from Baseline

  23. White Matter Microstructure as Measured by NODDI (intracellular volume fraction [ICVF], isotropic volume fraction [ISOVF], and Orientation Dispersion Index [ODI])

    ICVF, and ISOVF, ODI (dimensionless, 0-1) derived from NODDI modelling of multi-shell diffusion MRI data

    Time frame: Baseline & Change from Baseline

  24. White Matter Hyperintensity Volume as Measured by FLAIR MRI

    Total white matter hyperintensity volume (mL) segmented from T2-weighted FLAIR images

    Time frame: Baseline & Change from Baseline

  25. Cerebrovascular Reactivity (CVR) as Measured by BOLD fMRI with End-Tidal CO₂ (EtCO₂) Challenge

    CVR (expressed as % BOLD signal change per mmHg EtCO₂) derived from BOLD fMRI acquired during a hypercapnic EtCO₂ challenge

    Time frame: Baseline & Change from Baseline

  26. Neuroinflammation proxy as Measured by T2* relaxation times

    Milliseconds (ms)

    Time frame: Baseline & Change from Baseline

  27. Neuromelanin Contrast Ratio in the Substantia Nigra as Measured by Neuromelanin-Sensitive MRI

    Ratio of T1 signal intensity in the substantia nigra pars compacta relative to a reference region (dimensionless), used as an indirect in vivo measure of neuromelanin content

    Time frame: Baseline & Change from Baseline

  28. Intracranial Artery Lumen Diameter as Measured by Time-of-Flight MRA

    Lumen diameter (mm) measured at standardized segments of the ICA, MCA, basilar, and vertebral arteries using 3D TOF-MRA at 3T

    Time frame: Baseline & Change from Baseline

  29. Body Mass Index (BMI)

    BMI (kg/m²) calculated from measured height (m) and body weight (kg)

    Time frame: Baseline & Change from Baseline

  30. Waist Circumference, Hip Circumference

    circumference (cm)

    Time frame: Baseline & Change from Baseline

  31. Waist-to-height ratio, Waist-to-hip ratio

    Unitless

    Time frame: Baseline & Change from Baseline

  32. Visceral Adipose Tissue as Measured by MRI

    Visceral adipose tissue volume (mL) quantified by MRI Dixon sequence and Bioimpedance Analysis

    Time frame: Baseline & Change from Baseline

  33. Subcutaneous Adipose Tissue as Measured by MRI

    Subcutaneous adipose tissue volume (mL) quantified by MRI

    Time frame: Baseline & Change from Baseline

  34. Body Composition

    Whole-body fat as a percentage of total body mass (%), lean mass tissue, muscle mass measured by BIA

    Time frame: Baseline & Change from Baseline

Secondary outcomes

  1. Delay Discounting Task Score (Impulsive Choice)

    The Delay Discounting Task quantifies impulsive choice by measuring preference for smaller immediate versus larger delayed rewards. The discounting rate (k value, log-transformed) is the primary output; higher k values indicate greater impulsivity.

    Time frame: Baseline & Change from Baseline

  2. Penn Line Orientation Test Score (Visual Processing)

    The Penn Line Orientation Test (PLOT) assesses visuospatial processing by asking participants to match line orientations. Higher scores indicate better visual processing performance.

    Time frame: Baseline & Change from Baseline

  3. Penn Progressive Matrices Score (Fluid Intelligence)

    The Penn Progressive Matrices is a nonverbal test of fluid reasoning and abstract problem-solving. Higher scores indicate greater fluid intelligence.

    Time frame: Baseline & Change from Baseline

  4. Oral Reading Recognition Test Score (Language Ability)

    The Oral Reading Recognition Test assesses language ability and reading recognition. Scores are reported as raw scores; higher scores indicate better language performance.

    Time frame: Baseline & Change from Baseline

  5. Penn Word Memory Test Score (Episodic Memory)

    The Penn Word Memory Test assesses verbal episodic memory via a word recognition paradigm. Performance is reported as percentage of words correctly recognized (0-100%); higher values indicate better episodic memory.

    Time frame: Baseline & Change from Baseline

  6. Relational Memory Task Score (Executive Function and Attention)

    The Relational Task assesses relational reasoning and executive attention. Performance is reported as \[% correct / reaction time in ms\]; \[higher accuracy / lower reaction time\] indicates better performance.

    Time frame: Baseline & Change from Baseline

  7. Montreal Cognitive Assessment (MoCA) Total Score

    The MoCA is a brief cognitive screening tool assessing multiple domains including memory, attention, language, and visuospatial ability. Scores range from 0 to 30; higher scores indicate better global cognitive function.

    Time frame: Baseline & Change from Baseline

  8. Patient Health Questionnaire-9 (PHQ-9) Depression Score

    The PHQ-9 is a 9-item validated self-report questionnaire measuring depressive symptom severity over the preceding 2 weeks. Scores range from 0 to 27; higher scores indicate greater depressive symptom severity.

    Time frame: Baseline & Change from Baseline

  9. Mean Daily Energy Intake, fat, carbohydrate, sugar, protein intake, saturated fatty acids intake as Assessed by 3-Day Food Record.

    Daily energy intake from different macronutrients (kcal/day) derived from a 3-day food record and.

    Time frame: Baseline & Change from Baseline

  10. Percentage of calories derived from each of NOVA food classification categories

    Units: Percentage (%)

    Time frame: Baseline & Change from Baseline

  11. Healthy Eating Index

    The Healthy Eating Index (HEI) measures diet quality on a scale of 0 to 100, where 100 indicates perfect alignment with the Dietary Guidelines for Americans

    Time frame: Baseline & Change from Baseline

  12. Fat Taste Preference Score

    Geometric average of a preferred solution from a Monell 2-series forced choice test.

    Time frame: Baseline & Change from Baseline

  13. Sweet Taste Preference Score

    Geometric average of a preferred solution from a Monell 2-series forced choice test.

    Time frame: Baseline & Change from Baseline

  14. Working memory capacity

    Digits remembered on the digit span and digit span backwards task

    Time frame: Baseline & Change from Baseline

  15. Reinforcement learning outcomes

    Choose-A accuracy (reward learning) Proportion of test-phase trials on which participants select stimulus A (the most frequently rewarded stimulus, 80% positive feedback) when paired with novel stimuli, indexing the bias to learn from positive feedback / approach the best option. Avoid-B accuracy (punishment learning) Proportion of test-phase trials on which participants avoid stimulus B (the most frequently punished stimulus, 80% negative feedback) when paired with novel stimuli, indexing the bias to learn from negative feedback / avoid the worst option.

    Time frame: Baseline & Change from Baseline

08

Study locations

1 of 1 sites recruiting
  • The Montreal Neurological Institute-Hospital
    Montreal, Quebec H3A 2B4, Canada
    Recruiting
    • Alain Dagher, MD · Principal investigator
09

References and documents

Individual participant data

Plan to share: Yes — All anonymised and de-identified IPD (not biological samples) will be available to researchers on a case by case basis after trial completion.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: After trial completion with no end date.

Access criteria: Researchers will register to the portal and agree to terms and conditions of data use after which they will gain access to the IPD.

Data sharing details ↗ · cbigr-open.loris.ca

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 25 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 25 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2026
First posted
May 18, 2026
StartActual
Oct 21, 2026was Aug 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jun 1, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
The Montreal Neurological Institute-Hospital is now Recruiting
Oct 26, 2026
Start date
Aug 1, 2026→Oct 21, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    The Montreal Neurological Institute-Hospital is now Recruiting
    Start date Aug 1, 2026→Oct 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07592546
Lead sponsor
Alain Dagher
Responsible party
Alain Dagher (Principal Investigator, McGill University) — Sponsor-investigator
First posted
May 18, 2026
Start date
Oct 21, 2026
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Michael Pileggi, M.Sc.
Contact
michael.pileggi@mcgill.ca
514-396-2085
Filip Morys
Contact
filip.morys@mcgill.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion